参考文献/References:
[1] MAZZONE P J, SEARS C R, ARENBERG D A, et al.Evaluating molecular biomarkers for the early detectionof lung cancer: when is a biomarker ready for clinicaluse? an Official American Thoracic Society PolicyStatement[J]. American Journal of Respiratory andCritical Care Medicine, 2017, 196(7): e15-e29.
[2] MURTAZA M,DAWSON S J,POGREBNIAK K,etal. Multifocal clonal evolution characterized usingcirculating tumour DNA in a case of metastatic breastcancer[J]. Nature communications, 2015, 6:8760.
[3] SIRAVEGNA G, MUSSOLIN B, BUSCARINO M, etal. Clonal evolution and resistance to EGFR blockadein the blood of colorectal cancer patients[J]. NatureMedicine, 2015, 21(7): 795-801.
[4] SIRAVEGNA G, MARSONI S, SIENA S, et al.Integrating liquid biopsies into the management ofcancer[J]. Nature Reviews Clinical Oncology, 2017,14(9): 531-548.
[5] SIEGEL R L, MILLER K D, JEMAL A. Cancerstatistics,2019[J]. CA-A Cancer Journal for Clinicians,2019, 69(1): 7-34.
[6] SORIA F, SHARIAT S F, LERNER S P, et al.Epidemiology, diagnosis, preoperative evaluationand prognostic assessment of upper-tract urothelialcarcinoma (UTUC)[J]. World Journal of Urology, 2017,35(3): 379-387.
[7] MATSUMOTO K, NOVARA G, GUPTA A, et al.Racial differences in the outcome of patients withurothelial carcinoma of the upper urinary tract: aninternational study[J]. BJU International, 2011, 108(8Pt 2): E304-E309.
[8] SINGLA N, FANG Dong, SU Xiaohong, et al. Amulti-institutional comparison of clinicopathologicalcharacteristics and oncologic outcomes of upper tracturothelial carcinoma in China and the United States[J].The Journal of Urology, 2017, 197(5): 1208-1213.
[9] CHOU Y H, HUANG C H. Unusual cl inicalpresentation of upper urothelial carcinoma in Taiwan[J].Cancer, 1999, 85(6): 1342-1344.
[10] ZHANG Chufeng ,GUAN Yan, SUN Yulan, et al.Tumor heterogeneity and circulating tumor cells[J].Cancer Letters, 2016, 374(2): 216-223.
[11] SOAVE A, RIETHDORF S, DAHLEM R, et al.Detection and oncological effect of circulating tumourcells in patients with variant urothelial carcinomahistology treated with radical cystectomy[J]. BJUInternational, 2017, 119(6): 854-861.
[12] ZHANG Zheng, FAN Wei, DENG Qiaoling, et al.The prognostic and diagnostic value of circulatingtumor cells in bladder cancer and upper tract urothelialcarcinoma: a meta-analysis of 30 published studies[J].Oncotarget, 2017, 8(35): 59527-59538.
[13] ALIX-PANABIERES C, PANTEL K. Clinicalapplications of circulating tumor cells and circulatingtumor DNA as liquid biopsy[J]. Cancer Discovery,2016, 6(5): 479-491.
[14] STOTT S L, LEE R J, NAGRATH S, et al. Isolationand characterization of circulating tumor cells frompatients with localized and metastatic prostatecancer[J]. Science Translational Medicine, 2010, 2(25):25ra23.
[15] ILYAS A, ASGHAR W, KIM Y T, et al. Parallelrecognition of cancer cells using an addressable array ofsolid-state micropores[J]. Biosensors & Bioelectronics,2014, 62: 343-349.
[16] 李蜀婧, 王杨, 张克勤. 循环肿瘤细胞检测技术研究进展[J]. 免疫学杂志,2020,36(5):457-460.LI Shujing, WANG Yang, ZHANG Keqin. Theadvances in the detection of circulating tumor cells [J].Immunological Journal, 2020, 36(5): 457-460.
[17] DAGO A E, STEPANSKY A, CARLSSON A, et al.Rapid phenotypic and genomic change in response totherapeutic pressure in prostate cancer inferred by highcontent analysis of single circulating tumor cells[J].PLoS One, 2014, 9(8): e101777.
[18] LOHR J G, ADALSTEINSSON V A, CIBULSKISK A, et al. Whole-exome sequencing of circulatingtumor cells provides a window into metastatic prostatecancer[J]. Nature Biotechnology, 2014, 32(5): 479-484.
[19] HUO Ying, YAN Zhiqiang , YUAN Peng,et al.Single-cell DNA methylation sequencing revealsepigenetic alterations in mouse oocytes superovulatedwith different dosages of gonadotropins[J]. ClinicalEpigenetics, 2020, 12(1): 75.
[20] OSSANDON M R, AGRAWAL L, BERNHARD E J,et al. Circulating tumor DNA assays in clinical cancerresearch[J]. Journal of the National Cancer Institute,2018, 110(9): 929-934.
[21] GORGANNEZHAD L, UMER M, ISLAM M N,et al. Circulating tumor DNA and liquid biopsy:opportunities, challenges, and recent advances indetection technologies[J]. Lab on a Chip, 2018, 18(8):1174-1196.
[22] MERKER J D, OXNARD G R, COMPTON C, etal. Circulating tumor DNA analysis in patients withcancer:American Society of Clinical Oncology andCollege of American Pathologists joint review[J].Journal of Clinical Oncology, 2018, 36(16): 1631-1641.
[23] HUANG Weilun, CHEN Yilin, YANG S C, et al. Liquidbiopsy genotyping in lung cancer: ready for clinicalutility[J]. Oncotarget, 2017, 8(11): 18590-18608.
[24] WAN J C, MASSIE C, GARCIA-CORBACHO J, et al.Liquid biopsies come of age: towards implementationof circulating tumour DNA[J]. Nature Reviews Cancer,2017, 17(4): 223-238.
[25] AGARWAL N, PAL S K, HAHN A W, et al. Characterizationof metastatic urothelial carcinoma via comprehensivegenomic profiling of circulating tumor DNA[J].Cancer, 2018, 124(10): 2115-2124.
[26] CAI Dongyang, BEHRMANN O, HUFERT F, et al.Direct DNA and RNA detection from large volumes ofwhole human blood[J]. Scientific Reports, 2018, 8(1):3410.
[27] COHEN J D, LI Lu, WANG Yuxuan, et al. Detectionand localization of surgically resectable cancers with amulti-analyte blood test[J]. Science, 2018, 359(6378):926-930.
[28] CASTRO-GINER F, GKOUNTELA S, DONATO C, etal. Cancer diagnosis using a liquid biopsy: challengesand expectations[J]. Diagnostics (Basel, Switzerland),2018, 8(2): 31.
[29] LI Yifan, HE Shiming , HE Anbang , et al. Identificationof plasma secreted phosphoprotein 1 as a novelbiomarker for upper tract urothelial carcinomas[J].Biomedicine & Pharmacotherapy, 2019, 113: 108744.
[30] LEE D J, XYLINAS E, RIEKEN M, et al. Insulinlikegrowth factor messenger RNA-binding protein 3expression helps prognostication in patients with uppertract urothelial carcinoma[J]. European Urology, 2014,66(2): 379-385.
[31] ZEUSCHNER P, LINXWEILER J, JUNKER K.Non-coding RNAs as biomarkers in liquid biopsieswith a special emphasis on extracellular vesicles inurological malignancies[J].Expert Review of MolecularDiagnostics, 2020, 20(2): 151-167.
[32] MIYAKE M, OWARI T, HORI S, et al. Emergingbiomarkers for the diagnosis and monitoring ofurothelial carcinoma[J]. Research and Reports inUrology, 2018, 10: 251-261.
[33] IZQUIERDO L, INGELMO-TORRES M, MALLOFR?C, et al. Prognostic value of microRNA expressionpattern in upper tract urothelial carcinoma[J]. BJUInternational, 2014, 113(5): 813-821.
[34] TAO Jun, YANG Xiao, LI Pengchao, e t a l .Identification of circulating microRNA signatures forupper tract urothelial carcinoma detection[J]. MolecularMedicine Reports, 2015, 12(5): 6752-6760.
[35] KE Hunglung, LI Weiming, LIN Huihui, et al.Hypoxia-regulated microRNA-210 overexpression isassociated with tumor development and progressionin upper tract urothelial carcinoma[J]. InternationalJournal of Medical Sciences, 2017, 14(6): 578-584.
[36] BROWNE B M, STENSLAND K D, PATEL C K, et al.MicroRNA expression profiles in upper tract urothelialcarcinoma differentiate tumor grade, stage, andsurvival: implications for clinical Decision-Making[J].Urology, 2019, 123: 93-100.
[37] HSIAO K Y, SUN H S, TSAI S J. Circular RNA - newmember of noncoding RNA with novel functions[J].Experimental Biology and Medicine, 2017, 242(11):1136-1141.
[38] KRISTENSEN L S, HANSEN T B, VEN? M T, et al.Circular RNAs in cancer: opportunities and challengesin the field[J]. Oncogene, 2018, 37(5): 555-565.
[39] TANAKA N, KIKUCHI E, MATSUMOTO K, et al.Prognostic value of plasma fibrinogen levels in patientswith localized upper tract urothelial carcinoma[J]. BJUInternational, 2013, 111(6): 857-864.
[40] SUYAMA T, NAKAJIMA K, KANBE S, et al.Prognostic significance of preoperative serum CYFRA21-1 in patients with upper urinary tract urothelialcarcinoma[J]. International Journal of Urology, 2011,18(1): 43-47.
[41] ADVENIER A S, CASALEGNO J S, MEKKI Y, et al.Genotyping of high-risk human papillomaviruses inp16/Ki-67-positive urothelial carcinoma cells: even aworm will turn[J]. Cytopathology, 2015, 26(2): 106-113.
[42] COSKUNER E, CEVIK I, OZKAN A, et al. Inthe cystoscopic follow-up of non-muscle-invasivetransitional cell carcinoma, NMP-22 works for highgrades, but unreliable in low grades and upper urinarytract tumors[J]. International Urology and Nephrology,2012, 44(3): 793-798.
[43] JOVANOVIC M, HADZI-DJOKIC J, DZAMIC Z, etal. Evaluation of the bard BTA-test in the diagnosisof upper urinary tract tumours[J]. Acta ChirurgicaIugoslavica, 2007, 54(4): 19-24.
[44] TANG M K S, WONG A S T. Exosomes: emergingbiomarkers and targets for ovarian cancer[J]. CancerLetters, 2015, 367(1): 26-33.
[45] LEMOINNE S, THABUT D, HOUSSET C, et al. Theemerging roles of microvesicles in liver diseases[J].Nature Reviews Gastroenterology & Hepatology, 2014,11(6): 350-361.
[46] LEE D H, YOON H, PARK S, et al. Urinary exosomaland cell-free DNA detects somatic mutation and copynumber alteration in urothelial carcinoma of bladder[J].Scientific Reports, 2018, 8(1): 14707.
[47] LIN S Y, CHANG C H, WU H C, et al. Proteomeprofiling of urinary exosomes identifies alpha1-antitrypsin and H2B1K as diagnostic and prognosticbiomarkers for urothelial carcinoma[J]. ScientificReports, 2016, 6: 34446.
[48] ROUPR?T M, BABJUK M, COMP?RAT E, et al.European association of urology guidelines on upperurinary tract urothelial carcinoma: 2017 update[J].European Urology, 2018, 73(1): 111-122.
[49] FONT A, LUQUE R, VILLA J C, et al. The challengeof managing bladder cancer and upper tract urothelialcarcinoma: a review with treatment recommendationsfrom the Spanish oncology genitourinary group(SOGUG)[J]. Targeted Oncology, 2019, 14(1): 15-32.
[50] AUDENET F, YATES D R, CUSSENOT O, et al. Therole of chemotherapy in the treatment of urothelial cellcarcinoma of the upper urinary tract (UUT-UCC)[J].Urologic Oncology, 2013, 31(4): 407-413.
[51] MOSS T J, QI Yuan, XI Liu, et al. Comprehensivegenomic characterization of upper tract urothelialcarcinoma[J]. European Urology, 2017, 72(4): 641-649.